Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment

Immune checkpoint inhibitor (ICI) activates host’s anti-tumor immune response by blocking negative regulatory immune signals. A series of clinical trials showed that ICI could effectively induce tumor regression in a subset of advanced cancer patients. In clinical practice, a main concerning for cho...

Descripción completa

Detalles Bibliográficos
Autores principales: Yi, Ming, Jiao, Dechao, Qin, Shuang, Chu, Qian, Wu, Kongming, Li, Anping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6441150/
https://www.ncbi.nlm.nih.gov/pubmed/30925919
http://dx.doi.org/10.1186/s12943-019-0974-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6441150/
https://www.ncbi.nlm.nih.gov/pubmed/30925919
http://dx.doi.org/10.1186/s12943-019-0974-6

Ejemplares similares